The comparative effectiveness of fourth-line drugs in resistant hypertension: An application in electronic health record data.
Sarah-Jo SinnottLiam SmeethElizabeth WilliamsonPablo PerelDorothea NitschLaurie A TomlinsonIan J DouglasPublished in: Pharmacoepidemiology and drug safety (2019)
A higher rate of all-cause death in the AA group was likely due to unmeasured confounding in our analysis of the composite primary outcome, supported by our negative outcome analysis. Results for cardiovascular outcomes were plausible, but imprecise due to small cohort sizes and a low number of observed outcomes.